Changes in Wuchereria bancrofti infection in a highly endemic community following 10 rounds of mass administration of diethylcarbamazine

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 101, Issue 3, 2007, Pages 250-255

  Ramaiah, K D ^a   Vanamail, P ^a   Das, P K ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Circulating filarial antigen; Diethylcarbamazine; India; Lymphatic filariasis; Mass drug administration

Indexed keywords

DIETHYLCARBAMAZINE; PARASITE ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; ENDEMIC DISEASE; FEMALE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MICROFILARIASIS; PREVALENCE; SINGLE DRUG DOSE; WUCHERERIA BANCROFTI;

ADULT; AGED; ANIMALS; ANTIGENS, HELMINTH; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DIETHYLCARBAMAZINE; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; ELEPHANTIASIS, FILARIAL; ENDEMIC DISEASES; FEMALE; FILARICIDES; HUMANS; INDIA; MALE; MIDDLE AGED; PARASITEMIA; WUCHERERIA BANCROFTI;

WUCHERERIA BANCROFTI;

EID: 33845924601     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2006.05.007     Document Type: Article

References (35)

1. Babu B.V., and Kar S.K. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop. Med. Int. Health 9 (2004) 702-709
2. Bockarie M.J., Tisch D.J., Kastens W., Alexander N.D., Dimber Z., Bockarie F., Ibam E., Alpers M.P., and Kazura J.W. Mass treatment to eliminate filariasis in Papua New Guinea. N. Eng. J. Med. 23 (2002) 1841-1848
3. Chanteau S., Moulia-Pelat J.P., Glaziou P., Nguyen N.L., Luquiaud P., Plichart C., Martin P.M.V., and Cartel J.L. Og4C3 circulating antigen: a marker of infection and adult worm burden in Wuchereria bancrofti filariasis. J. Infect. Dis. 120 (1994) 247-250
4. Das P.K., Ramaiah K.D., Vanamail P., Pani S.P., Yuvaraj J., Balarajan K., and Bundy D.A.P. Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India. Trans. R. Soc. Trop. Med. Hyg. 95 (2001) 336-341
5. de Rochars M.B., Kanjilal S., Direny A.N., Radday J., Lafontant J.G., Mathieu E., Rheingans R.D., Haddix A.C., Streit T.G., Beach M.J., Addiss D.G., and Lammie P.J. The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration. Am. J. Trop. Med. Hyg. 73 (2005) 888-894
6. Eberhard M.L., Hightower A.W., Addiss D.G., and Lammie P.J. Clearance of Wuchereria bancrofti antigen after treatment with diethylcarbamazine or ivermectin. Am. J. Trop. Med. Hyg. 57 (1997) 483-486
7. Farid H.A., Hammad R.E., Soliman D.A., El Setouhy M., Ramzy R.M.R., and Weil G.J. Relationships between Wuchereria bancrofti microfilaraemia in human blood and parasite uptake and maturation in Culex pipiens, with observations on the effect of diethylcarbamazine treatment on these parameters. Am. J. Trop. Med. Hyg. 68 (2003) 286-293
8. Fraser M., Taleo G., Taleo F., Yaviong J., Amos M., Babu M., and Kalkoa M. Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach. Am. J. Trop. Med. Hyg. 73 (2005) 753-758
9. Freedman D.O., Plier D.A., de Almeida A.B., de Oliveira A.L., Miranda J., and Braga C. Effect of aggressive prolonged diethylcarbamazine therapy on circulating antigen levels in bancroftian filariasis. Trop. Med. Int. Health 6 (2001) 37-41
10. Hairston N.G., and Jachowski L.A. Analysis of the Wuchereria bancrofti population in the people of American Samoa. Bull. World Health Organ. 38 (1968) 29-59
11. Ismail M.M., Weil G.J., Jayasinghe K.S.A., Premaratne U.N., Abeyewickreme W., Rajaratnam H.N., Sheriff H.R., Perera C.S., and Dissanaike A.S. Prolonged clearance of microfilaraemia in patients with bancroftian filariasis after multiple high doses of ivermectin or diethylcarbamazine. Trans. R. Soc. Trop. Med. Hyg. 90 (1996) 684-688
12. Kazura J., Greenberg J., Perry R., Weil G.J., Day K., and Alpers M. Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea. Am. J. Trop. Med. Hyg. 49 (1993) 804-811
13. Leeuwin R.S. Microfilaraemia in Surinamese living in Amsterdam. Trop. Geogr. Med. 14 (1962) 355-360
14. McCarthy J.S., Guinea A., Weil G.J., and Ottesen E.A. Clearance of circulating filarial antigen as a measure of the macrofilaricidal activity of diethylcarbamazine in Wuchereria bancrofti infection. J. Infect. Dis. 172 (1995) 521-526
15. Meyrowitsch D.W., Simonsen P.E., and Magesa S.M. Long-term effect of three different strategies for mass diethylcarbamazine administration in bancroftian filariasis: follow-up at 10 years after treatment. Trans. R. Soc. Trop. Med. Hyg. 98 (2004) 627-634
16. Nicolas L., Plichart C., Nguyen L.N., and Moulia-Pelat J.P. Reduction of Wuchereria bancrofti adult worm circulating antigen after annual treatments of diethylcarbamazine combined with ivermectin in French Polynesia. J. Infect. Dis. 175 (1997) 489-492
17. Pani S.P., Hoti S.L., Elango A., Yuvaraj Y., Lal R., and Ramaiah K.D. Evaluation of ICT whole blood antigen card test to detect infection due to nocturnally periodic Wuchereria bancrofti in south India. Trop. Med. Int. Health 5 (2000) 359-363
18. Pani S.P., Subramaniam Reddy G., Das L.K., Vanamail P., Hoti S.L., Ramesh J., and Das P.K. Tolerability and efficacy of single dose albendazole, Diethylcarbamazine citrate (DEC) or co-administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, south India: a hospital based study. Filaria J. 1 (2002) 1-11
19. Rajendran R., Sunish I.P., Mani T.R., Munirathinam A., Abdullah S.M., Arunachalam N., and Satyanarayana K. Impact of two annual single-dose mass drug administrations with diethylcarbamazine alone or in combination with albendazole on Wuchereria bancrofti microfilaraemia and antigenaemia in south India. Trans. R. Soc. Trop. Med. Hyg. 98 (2004) 174-181
20. Ramaiah K.D., Das P.K., and Dhanda V. Estimation of permissible levels of transmission of bancroftian filariasis based on some entomological and parasitological results of a 5-year vector control programme. Acta Trop. 56 (1994) 89-96
21. Ramaiah K.D., Das P.K., Appavoo N.C., Ramu K., Augustin D.J., Vijay Kumar K.N., and Chandrakala A.V. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single dose DEC mass treatment and some related operational aspects. Trop. Med. Int. Health 5 (2000) 842-847
22. Ramaiah K.D., Vanamail P., Pani S.P., Yuvaraj J., and Das P.K. The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination. Trop. Med. Int. Health 7 (2002) 767-774
23. Ramaiah K.D., Vanamail P., Pani S.P., Yuvaraj J., and Das P.K. The prevalence of Wuchereria bancrofti antigenaemia in communities given six rounds treatment with diethylcarbamazine, ivermectin or placebo tablets. Ann. Trop. Med. Parasitol. 97 (2003) 737-741
24. Ramaiah K.D., Vanamail P., Pani S.P., Yuvaraj J., and Das P.K. The impact of six rounds of single dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus. Trop. Med. Int. Health 8 (2003) 1-11
25. Ramzy R.M., El Setouhy M., Helmy H., Kandil A.M., Ahmed E.S., Farid H.A., Faris R., and Weil G.J. The impact of single-dose diethylcarbamazine treatment of bancroftian filariasis in a low-endemicity setting in Egypt. Am. J. Trop. Med. Hyg. 67 (2002) 196-200
26. Schuetz A., Addiss D.G., Eberhard M.L., and Lammie P.J. Evaluation of the whole blood filariasis ICT test for short-term monitoring after antifilarial treatment. Am. J. Trop. Med. Hyg. 62 (2000) 502-503
27. Simonsen P.E., Magesa S.M., Meyrowitsch D.W., Malecela-Lazaro M.N., Rwegoshora R.T., Jaoko W.G., and Michael E. The effect of eight half-yearly single-dose treatments with DEC on Wuchereria bancrofti circulating antigenaemia. Trans. R. Soc. Trop. Med. Hyg. 99 (2005) 541-547
28. Stolk W.A., Ramaiah K.D., Van Oortmarssen G.J., Das P.K., Habbema J.D.F., and De Vlas S.J. Meta-analysis of age-prevalence patterns in lymphatic filariasis: no decline in microfilaraemia prevalence in older age groups as predicted by models with acquired immunity. Parasitology 129 (2004) 605-612
29. Subramanian S., Habbema J.D.F., Ramaiah K.D., Stolk W.A., Krishnamoorthy K., van Oortmarssen G.J., Amalraj D., Plaisier A.P., and Das P.K. The dynamics of Wuchereria bancrofti infection: a model-based analysis of longitudinal data from Pondicherry, India. Parasitology 128 (2004) 467-482
30. Vanamail P., Subramanian S., Das P.K., Pani S.P., and Rajagopalan P.K. Estimation of fecundic life span of Wuchereria bancrofti from longitudinal study of human infection in an endemic area of Pondicherry (south India). Ind. J. Med. Res. 91 (1990) 293-297
31. Weil G.J., Sethumadhavan K.V., Santhanam S., Jain D.C., and Ghosh T.K. Persistence of parasite antigenaemia following diethylcarbamazine therapy of bancroftian filariasis. Am. J. Trop. Med. Hyg. 38 (1988) 589-595
32. Weil G.J., Ramzy R.M., Chandrashekar R., Gad A.M., Lowrie Jr. R.C., and Faris R. Parasite antigenemia without microfilaremia in bancroftian filariasis. Am. J. Trop. Med. Hyg. 55 (1996) 333-337
33. Witt C., and Ottesen E.A. Lymphatic filariasis: an infection of childhood. Trop. Med. Int. Health 6 (2001) 582-606
34. WHO. Global programme to eliminate lymphatic filariasis. Wkly Epidemiol. Rec. 80 (2005) 202-212
35. WHO. Monitoring and epidemiological assessment of the programme to eliminate lymphatic filariasis at implementation unit level (2005), World Health Organization, Geneva WHO/CDS/CPE/CEE 2005.50